Telix Pharmaceuticals (ASX:TLX) Nears A Pixclara Decision, Is The Upside Already Priced In?
Telix Pharmaceuticals (ASX:TLX) is in focus after completing enrollment in its Phase 3 BiPASS study for prostate cancer imaging and as investors watch for an upcoming FDA decision on its Pixclara brain cancer imaging agent.
The recent BiPASS milestone and the upcoming Pixclara FDA decision are contributing to solid momentum for Telix Pharmaceuticals, with the share price at A$16.47 and a 90 day share price return of 23.74% contributing to a 5 year total shareholder return of 159.78%.
Scan for other biopharma stocks with clinical or regulatory momentum similar to Telix Pharmaceuticals by reviewing the curated 13 high quality undiscovered gems, which may still be flying under most investors' radar.
Given Telix Pharmaceuticals' strong recent share price move and upcoming clinical and FDA milestones that are not yet in current forecasts, is most of the upside already reflected in A$16.47, or is there still meaningful value on the table?
Most Popular Narrative: 29.5% Undervalued
On the most followed narrative, Telix Pharmaceuticals screens as undervalued, with a fair value of A$23.36 against the current A$16.47 share price. That narrative leans heavily on how clinical and regulatory catalysts could reshape earnings power over time.
Advancement of a broad late stage and early stage therapeutics pipeline across prostate cancer, kidney cancer, glioblastoma and other tumors, backed by increasing R&D spend and several pivotal or registration enabling trials, which, if successful, could shift the business mix toward higher value therapeutic revenue and influence long term net margins and earnings.
Read the complete narrative. Read the complete narrative.
Want to see why this fair value sits well above A$20 per share? The narrative focuses on faster top line growth, richer margins and a punchy earnings multiple. Curious how those moving parts add up to A$23.36 and what assumptions sit behind that discount rate and 2029 profit profile? That is where the full narrative earns a closer look.
Result: Fair Value of A$23.36 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Telix Pharmaceuticals still faces risks around rising R&D and manufacturing spend weighing on margins, as well as competitive PSMA imaging pressures that could affect pricing and profitability.
Find out about the key risks to this Telix Pharmaceuticals narrative.
Another View: What Multiples Say About Telix Pharmaceuticals
The first narrative leans on future earnings power to argue Telix Pharmaceuticals is undervalued. On current numbers, the picture is different. Telix trades on a P/E of 120.4x, compared with 25.8x for the global Biotechs industry, a 28.2x peer average and a fair ratio estimate of 52.9x. That leaves today’s share price looking full on this metric and raises the question of how much execution risk you are comfortable with.
For investors who like to stress test optimistic forecasts against today’s earnings multiple, the detailed ratio work in our valuation breakdown helps frame that risk and reward trade off See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
With Telix Pharmaceuticals showing both clear potential and some pointed concerns, it makes sense to review the data yourself and move promptly. To weigh both the upside case and the areas investors are worried about, start by reviewing these 3 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Telix Pharmaceuticals?
If you stop with Telix Pharmaceuticals, you could miss other compelling setups. Use the screener to quickly surface fresh ideas that match your risk and return preferences.
- Target potential mispricings by scanning a curated 10 high quality undervalued stocks that might line up better with your expectations on quality and price.
- Prioritise resilience by focusing on a list of solid balance sheet and fundamentals (21 results) so your next idea starts with financial strength rather than hidden weak spots.
- Reduce downside surprises by filtering through a 14 resilient stocks with low risk scores and concentrate your time on companies with more stable risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com